Determinants of Human Immunodeficiency Virus Type 1 Escape from the Primary CD8+ Cytotoxic T Lymphocyte Response

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2004 Nov 17

PMID 15545352

Citations 130

Authors

Nicola A Jones

Xiping Wei

Darren R Flower

Mailee Wong

Franziska Michor

Michael S Saag

Beatrice H Hahn

Martin A Nowak

George M Shaw

Persephone Borrow

Affiliations

Soon will be listed here.

Abstract

CD8+ cytotoxic T lymphocytes (CTLs) play an important role in containment of virus replication in primary human immunodeficiency virus (HIV) infection. HIV's ability to mutate to escape from CTL pressure is increasingly recognized; but comprehensive studies of escape from the CD8 T cell response in primary HIV infection are currently lacking. Here, we have fully characterized the primary CTL response to autologous virus Env, Gag, and Tat proteins in three patients, and investigated the extent, kinetics, and mechanisms of viral escape from epitope-specific components of the response. In all three individuals, we observed variation beginning within weeks of infection at epitope-containing sites in the viral quasispecies, which conferred escape by mechanisms including altered peptide presentation/recognition and altered antigen processing. The number of epitope-containing regions exhibiting evidence of early CTL escape ranged from 1 out of 21 in a subject who controlled viral replication effectively to 5 out of 7 in a subject who did not. Evaluation of the extent and kinetics of HIV-1 escape from >40 different epitope-specific CD8 T cell responses enabled analysis of factors determining escape and suggested that escape is restricted by costs to intrinsic viral fitness and by broad, codominant distribution of CTL-mediated pressure on viral replication.

Citing Articles

Revealing novel and conservative CD8T-cell epitopes with MHC B2 restriction on ALV-J.

Li X, Li Z, Ma M, Yang N, Du S, Liao M Vet Res. 2024; 55(1):164.

PMID: 39696681 PMC: 11654158. DOI: 10.1186/s13567-024-01426-3.

Functional variability of Nef in antagonizing SERINC5 during acute to chronic HIV-1 infection.

Li W, Li G, Liu Y, Meng L, Zhang T, Wang L AIDS. 2024; 39(3):229-240.

PMID: 39612239 PMC: 11784911. DOI: 10.1097/QAD.0000000000004079.

Energy demanding RNA and protein metabolism drive dysfunctionality of HIV-specific T cell changes during chronic HIV infection.

van Pul L, Stunnenberg M, Kroeze S, van Dort K, Boeser-Nunnink B, Harskamp A PLoS One. 2024; 19(10):e0298472.

PMID: 39356699 PMC: 11446443. DOI: 10.1371/journal.pone.0298472.

Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.

Cafaro A, Schietroma I, Sernicola L, Belli R, Campagna M, Mancini F Int J Mol Sci. 2024; 25(3).

PMID: 38338977 PMC: 10855115. DOI: 10.3390/ijms25031704.

No Difference in the Prevalence of HIV-1 Cytotoxic T-Lymphocyte-Associated Escape Mutations in Viral Sequences from Early and Late Parts of the HIV-1 Subtype C Pandemic in Botswana.

Mokaleng B, Choga W, Bareng O, Maruapula D, Ditshwanelo D, Kelentse N Vaccines (Basel). 2023; 11(5).

PMID: 37243104 PMC: 10221913. DOI: 10.3390/vaccines11051000.

References

Seiler P, Senn B, Klenerman P, Kalinke U, Hengartner H, Zinkernagel R . Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence. J Virol. 2000; 74(13):5896-901. PMC: 112085. DOI: 10.1128/jvi.74.13.5896-5901.2000. View

Mortara L, Letourneur F, Gras-Masse H, Venet A, Guillet J, Bourgault-Villada I . Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J Virol. 1998; 72(2):1403-10. PMC: 124619. DOI: 10.1128/JVI.72.2.1403-1410.1998. View

Kelleher A, Long C, Holmes E, Allen R, Wilson J, Conlon C . Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med. 2001; 193(3):375-86. PMC: 2195921. DOI: 10.1084/jem.193.3.375. View

McMichael A, Rowland-Jones S . Cellular immune responses to HIV. Nature. 2001; 410(6831):980-7. DOI: 10.1038/35073658. View

Borrow P, Shaw G . Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo?. Immunol Rev. 1998; 164:37-51. PMC: 7165923. DOI: 10.1111/j.1600-065x.1998.tb01206.x. View

Wagner R, Leschonsky B, Harrer E, Paulus C, Weber C, Walker B . Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication. J Immunol. 1999; 162(6):3727-34. View

Richman D . HIV chemotherapy. Nature. 2001; 410(6831):995-1001. DOI: 10.1038/35073673. View

Betts M, Ambrozak D, Douek D, Bonhoeffer S, Brenchley J, Casazza J . Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol. 2001; 75(24):11983-91. PMC: 116093. DOI: 10.1128/JVI.75.24.11983-11991.2001. View

Barouch D, Kunstman J, Kuroda M, Schmitz J, Santra S, Peyerl F . Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 2002; 415(6869):335-9. DOI: 10.1038/415335a. View

10.

Allen T, Mortara L, Mothe B, Liebl M, Jing P, Calore B . Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol. 2002; 76(8):4108-12. PMC: 136098. DOI: 10.1128/jvi.76.8.4108-4112.2002. View

11.

OConnor D, Allen T, Vogel T, Jing P, DeSouza I, Dodds E . Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med. 2002; 8(5):493-9. DOI: 10.1038/nm0502-493. View

12.

McMichael A, Hanke T . The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?. Nat Rev Immunol. 2002; 2(4):283-91. DOI: 10.1038/nri779. View

13.

Moore C, John M, James I, Christiansen F, Witt C, Mallal S . Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science. 2002; 296(5572):1439-43. DOI: 10.1126/science.1069660. View

14.

Stittelaar K, Gruters R, Schutten M, van Baalen C, van Amerongen G, Cranage M . Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine. 2002; 20(23-24):2921-7. DOI: 10.1016/s0264-410x(02)00219-0. View

15.

Yusim K, Kesmir C, Gaschen B, Addo M, Altfeld M, Brunak S . Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol. 2002; 76(17):8757-68. PMC: 136996. DOI: 10.1128/jvi.76.17.8757-8768.2002. View

16.

van Baalen C, Guillon C, van Baalen M, Verschuren E, Boers P, Osterhaus A . Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur J Immunol. 2002; 32(9):2644-52. DOI: 10.1002/1521-4141(200209)32:9<2644::AID-IMMU2644>3.0.CO;2-R. View

17.

OConnor D, Allen T, Watkins D . Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies. DNA Cell Biol. 2002; 21(9):659-64. DOI: 10.1089/104454902760330192. View

18.

Barouch D, Letvin N . Viral evolution and challenges in the development of HIV vaccines. Vaccine. 2002; 20 Suppl 4:A66-8. DOI: 10.1016/s0264-410x(02)00390-0. View

19.

Addo M, Yu X, Rathod A, Cohen D, Eldridge R, Strick D . Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 2003; 77(3):2081-92. PMC: 140965. DOI: 10.1128/jvi.77.3.2081-2092.2003. View

20.

Wei X, Decker J, Wang S, Hui H, Kappes J, Wu X . Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929):307-12. DOI: 10.1038/nature01470. View